VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TARAProtara Therapeutics, Inc.
$4.11$159M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTARARevenue History

TARA logoProtara Therapeutics, Inc. (TARA) Revenue History

Annual and quarterly revenue from 2012 to present

TTM Revenue$0
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$2.9M (2014)
Best Quarter$0 ()

TARA Revenue Over Time (2012–2025)

TARA Revenue Growth History

0 of 1 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2012—
2013—
2014—
2015-100.0%
2016—
2017—
2018—
2019—
2020—
2021—
2022—
2023—
2024—
2025—
FY2012 revenue growth
N/A
FY2013 revenue growth
N/A
FY2014 revenue growth
N/A
FY2015 revenue growth
-100.0%
FY2016 revenue growth
N/A
FY2017 revenue growth
N/A
FY2018 revenue growth
N/A
FY2019 revenue growth
N/A
FY2020 revenue growth
N/A
FY2021 revenue growth
N/A
FY2022 revenue growth
N/A
FY2023 revenue growth
N/A
FY2024 revenue growth
N/A
FY2025 revenue growth
N/A
DeclineStrong growth
Best: -100.0% (FY2015)Worst: -100.0% (FY2015)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0—
Q3 2024$0—
Q2 2024$0—

TARA Revenue Analysis (2012–2025)

Current Revenue & Growth

As of June 23, 2026, Protara Therapeutics, Inc. (TARA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

TARA's historical revenue data shows various trends over time. Protara Therapeutics, Inc.'s highest annual revenue of $2.9 million was recorded in 2014.

Peer Comparison

Compared to Healthcare sector peers — including FOLD (+20.0% YoY), RARE (+13.3% YoY), and ACAD (+9.9% YoY). Compare TARA vs FOLD →

TARA Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
TARA logoTARACurrent$0---
FOLD logoFOLD$634M+20.0%+19.4%5.4%
RARE logoRARE$673M+13.3%+19.9%-79.5%
ACAD logoACAD$1.1B+9.9%+19.4%9.8%
PRTA logoPRTA$10M-58.0%+62.6%-1905.8%
Best in groupLowest in group

TARA Historical Revenue Data (2012–2025)

1–14 of 14 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$-362,000-$-64,549,000-
2024$0-$0-$-49,154,000-
2023$0-$-341,000-$-43,613,000-
2022$0-$0-$-67,062,000-
2021$0-$0-$-47,489,000-
2020$0-$-196,000-$-34,444,000-
2019$0-$-16,000-$-15,254,000-
2018$0-$-115,000-$-26,080,000-
2017$0-$-148,000-$-30,362,000-
2016$0-$-123,000-$-28,705,000-
2015$0-100.0%$-57,000-$-20,870,000-
2014$2.9M-$2.9M100.0%$-7,580,000-257.1%
2013$0-$-27,000-$-7,122,000-
2012$0-$-57,000-$-7,996,000-
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TARA — Frequently Asked Questions

Quick answers to the most common questions about buying TARA stock.

Is TARA's revenue growth accelerating or slowing?

TARA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is TARA's revenue history from 2012 to 2026?

Protara Therapeutics, Inc. (TARA) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is TARA's long-term revenue growth rate (CAGR)?

Protara Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TARA.

Why does TARA's quarterly revenue fluctuate?

TARA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Protara Therapeutics, Inc.'s revenue data from 2012 to 2026 shows full historical quarterly detail on this page.

How is TARA's revenue distributed by segment?

TARA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does TARA's revenue compare to industry peers?

Protara Therapeutics, Inc. (TARA) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.